Simple blood or urine test could spot kidney cancer early
NCT ID NCT06339138
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study collects blood, tissue, and urine from about 589 people with different types of kidney or urinary tract tumors, plus healthy volunteers. Researchers are looking for special DNA markers (methylated DNA) that could help detect these cancers earlier and more accurately. The goal is to develop a simple, non-invasive test using blood or urine samples.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
589 people
The number who actually took part.
- Started
-
Jun 2018
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, urothelial cell carcinoma, or healthy participants who have undergone negative hematuria workups
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * CASE TISSUE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, clear cell papillary RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * CASE BLOODS AND URINE: * Patient has a histological diagnosis of primary clear cell RCC, papillary cell RCC, chromophobe RCC, oncocytoma, or urothelial cell carcinoma * Age \>= 18 years * HEALTHY CONTROL BLOODS AND URINE: * Patients has undergone negative hematuria workups (defined as negative abdominal imaging and negative cystoscopy * Age \>= 18 years Exclusion Criteria: * CASE TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD) * The current target pathology is a recurrence * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X * Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease * RENAL CONTROL TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD). * Patient has inflammation, atypia, or hyperplasia of the parenchyma * Patient has a current or past history of renal cancer. * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmation of Lynch Syndrome, is presumed to have Lynch Syndrome, or has familial cancer syndrome X * Patient has Nephritis (Glomerulus or Interstitial), Poly Cystic Kidney Disease, Glomerulonephropathies or Acquired Renal Kidney Disease * UROTHELIAL CONTROL TISSUE: * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD) * Patient has inflammation, atypia, or hyperplasia of the urothelium * Patient has a current or past history of urothelial cancer * Patient has undergone any prior radiation therapy to target lesion prior to surgery * Patient has received chemotherapy class drugs in the 5 years prior to surgery * Patient has had any transplants prior to surgery * Patient has confirmed or presumed lynch * CASE BLOODS AND URINE: * Patient has known primary cancer outside of the kidney within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers) * Patient has had surgery to completely or partially remove current target pathology * Patient has undergone any prior radiation therapy to target lesion prior to plasma and urine collection * Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection * Patient has had any transplants prior to plasma and urine collection * Patient has confirmed or presumed lynch * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dubé syndrome (BHD) * HEALTHY CONTROL BLOODS AND URINE: * Patient has known primary cancer outside of the urothelium within the last 5 years prior to plasma and urine collection (not including basal cell or squamous cell skin cancers) * Current target pathology is a recurrence * Patient has undergone prior radiation therapy in the 5 years prior to plasma and urine collection * Patient has received chemotherapy class drugs in the 5 years prior to plasma and urine collection * Patient has had any transplants prior to plasma and urine collection * Patient has von Hippel-Lindau disease (VHL), Hereditary leiomyomatosis and renal cell cancer (HLRCC), Hereditary papillary renal carcinoma (HPRC), or Birt-Hogg-Dube syndrome (BHD) * Patient has confirmed or presumed lynch * Gross urinary incontinence * Patient has undergone cystectomy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chromophobe renal cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can intensified chemotherapy before surgery clear bladder tumors?
- Chemo combo tested as backup for bladder cancer that outsmarts First-Line therapy
- Chemo gel delivered directly to kidney tumors: can it help when other options run out?
- Can tumor genes decide who keeps their bladder?
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target CD70 in kidney cancer